 | THE METABOLIC SYNDROME X: Convergence of Insulin Resistance, Glucose Intolerance, Hypertension, Obesity, and Dyslipidemias-Searching for the Underlying Defects
Copyright © 1999 by the New York Academy of Sciences
description
Annals of the New York Academy of Sciences 892:45-57 (1999)
© 1999 New York Academy of Sciences
Insulin Resistance: A Chicken That Has Come to Roost
GERALD M. REAVENa
Stanford University School of Medicine, Stanford, California 93405, USA
aAddress correspondence to G. M. Reaven, M.D., Shaman Pharmaceuticals, Inc., 213 East Grand Avenue, South San Francisco, CA 94080-4812. Tel: (650) 952-7070; fax: (650) 873-8377; e-mail: greaven{at}shaman.com
Insulin-mediated glucose disposal varies approximately 10-fold in apparently healthy human beings. Insulin (I)-resistant individuals can remain glucose tolerant if the pancreas compensates for this defect by secreting large amounts of I. Type 2 diabetes develops when I-resistant persons cannot sustain this state of compensatory hyperinsulinemia (  I). However, the ability of  I to prevent decompensation of glucose tolerance is a mixed blessing, and the combination of I resistance and  I predisposes such individuals to develop a series of abnormalities that increase risk of coronary heart disease (CHD). Given the health-related consequences of I resistance and  I, it has been suggested that a "thrifty" genotype exists that favored evolutionary survival by enhancing I secretion and thereby promoting energy accumulation. An alternative view is that conservation of muscle mass was necessary for survival, and that muscle I resistance was the "thrifty" genotype. This latter hypothesis is more consistent with current data, and there is evidence of a genetic basis for I resistance. In either case, there is little question as to the importance of I resistance and related abnormalities in diseases of Western civilization. However, the strength of the association between I resistance and its consequences varies in magnitude, and it is necessary to emphasize that development of a clinical end-point will vary as a function of (1) degree of I resistance; (2) "closeness" of I resistance to the end-point; and (3) the ability to compensate for the effects of I resistance. I resistance is a physiological characteristic, genetically determined, that helped primitive humans to survive. It is greatly aggravated by obesity and physical inactivity, and represents a modern scourge.
This article has been cited by other articles:

|
 |

|
 |
 
C. Li, E. S. Ford, L. C. McGuire, A. H. Mokdad, R. R. Little, and G. M. Reaven
Trends in hyperinsulinemia among nondiabetic adults in the u.s.
Diabetes Care,
November 1, 2006;
29(11):
2396 - 2402.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Durgan, J. K. Smith, M. A. Hotze, O. Egbejimi, K. D. Cuthbert, V. G. Zaha, J. R. B. Dyck, E. D. Abel, and M. E. Young
Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin
Am J Physiol Heart Circ Physiol,
June 1, 2006;
290(6):
H2480 - H2497.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. L. Blazer-Yost, J. C. Vahle, J. M. Byars, and R. L. Bacallao
Real-time three-dimensional imaging of lipid signal transduction: apical membrane insertion of epithelial Na+ channels
Am J Physiol Cell Physiol,
December 1, 2004;
287(6):
C1569 - C1576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Ran, T. Hirano, and M. Adachi
Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats
Am J Physiol Endocrinol Metab,
August 1, 2004;
287(2):
E227 - E232.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Lamarche and S. Desroches
Metabolic syndrome and effects of conjugated linoleic acid in obesity and lipoprotein disorders: the Quebec experience
Am. J. Clinical Nutrition,
June 1, 2004;
79(6):
1149S - 1152S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Bakken and C. D. Hunt
Dietary Boron Decreases Peak Pancreatic In Situ Insulin Release in Chicks and Plasma Insulin Concentrations in Rats Regardless of Vitamin D or Magnesium Status
J. Nutr.,
November 1, 2003;
133(11):
3577 - 3583.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M Lord, I. H K Flight, and R. J Norman
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
BMJ,
October 25, 2003;
327(7421):
951.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. D. Monti, C. Barlassina, L. Citterio, E. Galluccio, C. Berzuini, E. Setola, G. Valsecchi, P. Lucotti, G. Pozza, L. Bernardinelli, et al.
Endothelial Nitric Oxide Synthase Polymorphisms Are Associated With Type 2 Diabetes and the Insulin Resistance Syndrome
Diabetes,
May 1, 2003;
52(5):
1270 - 1275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. C. Wascher, B. Paulweber, L. Malaimare, A. Stadlmayr, B. Iglseder, I. Schmoelzer, and W. Renner
Associations of a Human G Protein {beta}3 Subunit Dimorphism With Insulin Resistance and Carotid Atherosclerosis
Stroke,
March 1, 2003;
34(3):
605 - 609.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Ramsay, W. R. Ferrell, L. Crawford, A. M. Wallace, I. A. Greer, and N. Sattar
Maternal Obesity Is Associated with Dysregulation of Metabolic, Vascular, and Inflammatory Pathways
J. Clin. Endocrinol. Metab.,
September 1, 2002;
87(9):
4231 - 4237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F Levi, C Pasche, F Lucchini, C La Vecchia, M S Sandhu, and K-T Khaw
Diabetes mellitus, family history, and colorectal cancer
J. Epidemiol. Community Health,
June 1, 2002;
56(6):
479 - 480.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Cantin, P. Wen, D. Zhu, M. Dai, S. N. Panchal, M. E. Billingham, J. K. Gwathmey, and H. A. Valantine
Transplant Coronary Artery Disease: A Novel Model Independent of Cellular Alloimmune Response
Circulation,
November 20, 2001;
104(21):
2615 - 2619.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Bagg, C. Ferri, G. Desideri, G. Gamble, P. Ockelford, and G. D. Braatvedt
The Influences of Obesity and Glycemic Control on Endothelial Activation in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab.,
November 1, 2001;
86(11):
5491 - 5497.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|